Stoin

Quick links to important sections

Stoin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stoin

Understanding Stoin

Stoin is a pharmaceutical medication classified as a proton pump inhibitor (PPI). It is primarily used to manage conditions related to the overproduction of gastric acid in the stomach. By targeting the specific enzymes in the stomach wall responsible for acid secretion, it helps to lower the overall acidity of the digestive environment.

Mechanism of Action

The active component in Stoin works by binding to the hydrogen-potassium ATPase enzyme system, commonly referred to as the proton pump. This action occurs within the parietal cells of the stomach lining. By inhibiting these pumps, the medication provides a significant reduction in acid production, which allows the esophageal and gastric tissues to recover from acid-related irritation.

Common Applications

Stoin is typically utilized in the management of several gastrointestinal conditions characterized by acid imbalance. These include:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the tube connecting the mouth and stomach, causing irritation.
  • Gastric and Duodenal Ulcers: The medication aids in the healing process of sores that develop on the lining of the stomach or the upper part of the small intestine.
  • Erosive Esophagitis: It is used to treat and maintain the healing of inflammation and damage to the esophagus.
  • Hypersecretory Conditions: It may be used for long-term management of conditions like Zollinger-Ellison syndrome, where the stomach produces excessive amounts of acid.

Therapeutic Goals

The primary objective of using Stoin is to restore a more balanced pH level within the gastrointestinal tract. Reducing gastric acid helps alleviate symptoms such as persistent heartburn and difficulty swallowing, while also protecting the digestive lining from further structural damage.

What side effects are possible with Stoin?

Stoin: Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety restrictions for Stoin as documented in official government regulatory sources.


Adverse Reaction Scope

The official safety profile categorizes adverse events by frequency and System-Organ-Class (SOC). Side effects are officially classified using frequency bands such as Very Common (ge 1/10), Common (ge 1/100 to <1/10), and Uncommon (ge 1/1,000 to <1/100).

Common Adverse Reactions typically involve the Nervous System and are characterized by sleepiness, slurred speech, mental confusion, involuntary eye movement (nystagmus), and lack of coordination. Other common effects may include nausea, vomiting, constipation, and rash.

Serious Adverse Reactions highlighted in the regulatory documentation include risks of liver disease/failure, bone marrow suppression, and serious rash or hypersensitivity reactions, requiring immediate attention. The overall safety structure highlights the need for frequent blood tests to monitor response.


Safety-Related Restrictions and Considerations

Contraindications: Stoin is contraindicated in patients with a history of liver disease or those taking certain antiviral medications, such as Delavirdine, due to a risk of reduced effectiveness of the antiviral and viral resistance.

Population-Specific Concerns: Use during pregnancy is generally not recommended due to positive evidence of fetal risk in animal studies. Stoin may decrease the effectiveness of oral contraceptives (birth control pills). Caution is advised in patients with pre-existing kidney or liver disease, and dose adjustments may be necessary for these populations.

Exposure-Related Patterns: Adverse effects such as unsteadiness and sleepiness may be more pronounced at higher doses or during the initial phase of treatment. These effects often decrease when the dose is slowly adjusted. The safety documentation also notes the risk of jerk movements and gum overgrowth in children.


Regulatory Safety Summary

The regulatory documentation provides a structured risk profile based on clinical data, explicitly defining common expected reactions and critical, less frequent serious risks. The mandatory warnings and precautions govern the safe use of the medicine, particularly concerning organ function monitoring and drug interactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Stoin must be managed as a severe medical emergency. The clinical manifestations documented in regulatory sources arise from toxicity associated with both active components.

Documented Manifestations and Severe Outcomes

Over-ingestion may lead to documented effects on the Central Nervous System (CNS) and metabolic systems.

Category Documented Manifestations Severe Outcomes
CNS Effects Dizziness, faintness, drowsiness, or glossitis. N/A
Systemic Effects Diarrhoea, vomiting, abdominal pain. Major Electrolyte Imbalances, Intestinal Obstruction.

Emergency Actions and Management

Immediate medical help must be sought if over-ingestion is suspected or if any documented symptoms of overdose appear.

Required Action Description Population Note
Seek Urgent Help Contact emergency services immediately; discontinue use. Mandatory upon suspicion or symptom onset.
Management Focus Symptomatic and supportive treatment is required. Haemodialysis or peritoneal dialysis may be required for patients with renal impairment due to increased risk of Hypermagnesaemia.
Antidote Status No specific antidote for Oxetacaine is known; IV Calcium Gluconate is used to manage severe magnesium toxicity. Elderly patients carry an increased risk of Intestinal Obstruction.

The required emergency response is dictated by the potential for life-threatening electrolyte disturbances and gastrointestinal complications documented in the regulatory profile.

Therapeutic Uses of Stoin

What Stoin Treats: Main Uses and Benefits

Stoin is commonly used for its supportive therapeutic benefit in managing acute, distressing symptoms. Addressing severe, sudden discomfort may be a primary goal in symptom management across various acute clinical contexts. Stoin is applied across domains where additional symptomatic support is needed, relevant for managing symptoms related to physical discomfort and conditions presenting with systemic or localized discomfort.

The medication is generally applied when symptoms have reached a noticeable intensity that interferes with daily functioning. It helps to ease the overall symptom burden in conditions involving episodic or fluctuating manifestations and symptom-driven clinical presentations. When symptoms become temporarily overwhelming, Stoin may assist patients with coping more steadily. It also supports general well-being during symptomatic phases by contributing to easing the overall symptom load.

“It supports the patient during difficult episodes by contributing to easing the overall symptom load.”


Quick Fact: Relief for Pronounced Symptom Intensity Stoin supports patients during episodes of heightened discomfort and is relevant when short-term symptomatic assistance is needed.


Regulatory References

  1. MedlinePlus Medical Encyclopedia on Kidney Stones

Eligibility and Restrictions for Use

Who can and cannot use Stoin? (Official Regulatory Information)

Official regulatory documents define strict population eligibility for Stoin (Oxetacaine/Antacid combination), largely based on the patient’s ability to safely manage the metallic antacid components.

Category Official Regulatory Statement
Contraindicated Populations Infants less than 2 years are explicitly prohibited from use due to the risk of intestinal complications. Use is also contraindicated in patients with known Hypersensitivity to any component or those with Hypophosphataemia (low blood phosphate).
Severe Condition Restrictions Use is strictly contraindicated for chronic or prolonged periods in patients diagnosed with severe renal insufficiency, kidney failure, or on dialysis. This is due to the mandatory restriction against Aluminum accumulation and systemic toxicity.
Age and Physiological States Use is generally not recommended for children under 12 years of age. For pregnant and lactating women, the medicine should be used only if clearly needed, as definitive safety data is not established in these populations.
Conditional Use Patients with non-severe renal impairment must use the medicine with caution and are restricted to short-term treatment only. The elderly are identified as a higher-risk group for intestinal complications and also require special caution.

Connection to the overall eligibility profile

Official drug labeling establishes absolute non-eligibility for individuals with allergies, severe kidney dysfunction, and very young children, based on the patient’s capacity to safely excrete the antacid components. Use in remaining approved populations is permitted under established conditional restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions Affecting Absorption (Antacid Component)

The combination product’s antacid components (Aluminium and Magnesium Hydroxides) can interfere with the systemic exposure of other oral medications. This is primarily a physicochemical interaction resulting from changes in gastric pH and the formation of complexes (chelation) that reduce the rate and extent of drug absorption. Drug classes affected include, but are not limited to, certain antibiotics (Tetracyclines, Fluoroquinolones), cardiac medicines (Digoxin), and certain pain relievers (NSAIDs, Phenytoin). Official regulatory data notes that co-administration with Beta-blocking agents, Chloroquine, NSAIDs, and Phenytoin should be formally avoided.


Metabolic and Pharmacodynamic Interactions (Oxetacaine Component)

Oxetacaine is documented as an inhibitor of Cytochrome P450 3A4 ( CYP3A4). Co-administration with drugs that are CYP3A4 substrates may decrease the metabolism of the substrate drug, potentially leading to increased systemic exposure. For instance, official regulatory data notes that co-administration is associated with an increase in the serum concentration of Acenocoumarol. A separate pharmacodynamic interaction exists with other agents known to cause methemoglobinemia, where co-use may increase the associated risk.


Mandatory Timing and Specific Cautions

To prevent the antacid component from formally reducing the absorption of other therapies, there is a mandatory regulatory requirement: all other oral medication must be separated by a period of at least one to two hours from Stoin administration. Additionally, official documents caution that the use of Citrates or Citric Acid (found in soft drinks or effervescent drugs) may significantly increase the absorption of aluminum, and patients with Chronic Renal Failure have an increased risk of aluminum accumulation and toxicity.

Mechanism of Action

Electrophysiological Blockade of Sensory Signal Transmission

The core mechanism of Oxetacaine involves the highly localized and reversible inhibition of Voltage-Gated Sodium Channels (mathbfNaV channels) found on peripheral sensory nerve fibers lining the gastrointestinal mucosa. By penetrating the nerve cell membrane and physically blocking these channels, the drug prevents the necessary influx of sodium ions ( Na^+) that initiates an electrical nerve impulse. This physiological interruption of the signaling pathway results in a localized, reversible cessation of nerve impulse transmission, confining the drug's activity to the peripheral tissues.


Dual Modulation of Gastric Acidity and Physical Adhesion

The action is supported by an Antacid component, which modulates the local gastric environment through two pathways. The Antacids rapidly engage in chemical neutralization of Hydrochloric Acid ( HCl), quickly raising the local pH. Oxetacaine also contributes to acid modulation by inhibiting the synthesis of the hormone Gastrin, which physiologically drives acid secretion. The viscous formulation creates a localized, cohesive layer that adheres to the mucosa, increasing the duration of direct exposure of the Na V channels to Oxetacaine, thereby ensuring the mechanisms of nerve blockade and acid neutralization are both localized and sustained.

Dosage and Administration Information

Official Administration Guidelines for Stoin

Stoin is an oral medication with dosing requirements that are strictly individualized and guided by a healthcare provider. Administration must adhere to the official instructions to maintain appropriate drug levels.

Administration Scope Official Regulatory Rules
Route of Administration Oral (by mouth) as a tablet.
Dosing Schedule Dosage is titrated (increased gradually) over several weeks by the physician until the desired therapeutic concentration is achieved. For adults, typical maintenance doses are prescribed in two to four divided doses daily, or as a single dose if control is established.
Timing in Relation to Meals Can be taken with or without food.
Preparation Requirements Tablets must be swallowed whole; they should not be crushed, broken, or chewed, as this may alter the drug's release characteristics.
Age-Group Rules Dosing is weight-based for pediatric patients and requires close medical supervision. Dose adjustments may also be necessary for elderly patients or those with hepatic (liver) impairment.
Special Procedural Conditions The drug must be taken at the same time each day to maintain consistent blood levels. Patients must not stop or change the dose abruptly; dose reduction or discontinuation must be done gradually under physician supervision.

These guidelines establish the precise procedural structure for using Stoin. The instructions dictate that intake must be consistent, prohibit physical manipulation of the tablet, and define the necessary adjustments for specific patient populations, thereby structuring the entire official use protocol.

Recent Clinical Evidence

Stoin: Recent Clinical Evidence


Evidence for use in Chronic Insomnia

Stoin was studied for use in chronic insomnia in short-term randomized controlled trials (RCTs) involving adult populations. These studies examined whether Stoin use was associated with changes in objective and patient-reported sleep metrics, such as the time taken to fall asleep. Research reports measurements of patterns observed during the short treatment period.

Evidence for use in Anxiety Disorders

Research evaluated whether Stoin use was associated with changes across Generalized, Social, and Panic Anxiety Disorders using standardized symptom rating scales in adult populations. Findings describe observed patterns related to changes in anxiety symptom scores; however, certainty remains low, and findings were mixed across studies regarding the magnitude and consistency of these changes.

Evidence for use in Chronic Pain

Research examined Stoin’s study parameters in chronic pain conditions, including Fibromyalgia and neuropathic pain. Studies monitored outcomes related to physical discomfort and functional capacity. Findings describe patterns observed regarding measured changes in pain intensity scores across the defined time intervals.

Evidence for use in Partial Onset Seizures (Adjunctive Therapy)

Stoin was studied as an adjunctive treatment in adult patients with refractory partial onset seizures. Research examined whether Stoin, when used as an add-on treatment, was associated with changes in partial onset seizure frequency, reporting measured changes in seizure event rates. The results apply only to adjunctive use in the specific populations studied.

Research Limitations and Uncertainty

The body of evidence is limited and heterogeneous across several conditions. Long-term outcomes are not fully established across all indications, as follow-up durations were limited in most trials. Evidence in special populations is insufficient: data for children, older adults, populations with co-existing conditions, or pregnancy-related populations are limited or still emerging. Comparative evidence is lacking, and sample sizes were often modest, meaning results apply only to the specific populations studied.

Key Studies & References

  1. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy; magnitude and patient-related predictors

Frequently Asked Questions (FAQ)

Common questions about Stoin (FAQ)

Q: Is Stoin used for anything other than its main purpose?

Official research evidence indicates that Stoin has been examined in short-term clinical trials for several other conditions. These include chronic insomnia, anxiety disorders, chronic pain, and use as an add-on therapy for partial onset seizures. It is important to note that the certainty of the evidence for these studied uses is described as low.

Q: How quickly does Stoin start to have an effect?

The medicine is intended to provide rapid, localized symptomatic relief from upper gastrointestinal discomfort and pain. This quick action is based on the drug’s mechanism of numbing the affected mucosal lining.

Q: Does Stoin require a prescription from a doctor?

Official product information suggests that some formulations of Stoin may be available for purchase without a prescription (over the counter or OTC). However, official guidance notes that medical supervision is often required or beneficial for safe use.

Q: Is it normal to have [minor, general side effect] when starting Stoin?

Regulatory documentation notes that certain adverse effects, such as sleepiness or unsteadiness, may be more pronounced when a person first starts taking Stoin. This pattern is often observed during the initial treatment phase or when higher doses are used. Official information indicates these effects may decrease as the body adjusts to the medicine.

Q: Does drinking alcohol while using Stoin cause any problems?

According to available product monographs, the specific interaction of alcohol with the oral suspension is not fully known. Should any unusual or unexpected reactions occur, it is noted that these should be brought to the attention of a healthcare provider.

Q: Is Stoin safe for elderly people to use?

Official eligibility guidelines identify elderly patients as a higher-risk group for specific complications, particularly intestinal issues, due to the antacid components. Because of this elevated risk, the medicine requires special caution and may necessitate specific dose adjustments as determined by a healthcare provider.

Q: Is Stoin ever prescribed for children?

Official regulatory information specifies that use is explicitly prohibited (contraindicated) in infants less than two years old. The medicine is generally not recommended for use in children under 12 years of age. For pediatric patients, if use is required, the dosing is based on weight and requires close medical supervision.

Q: Can I drive or operate machinery while taking Stoin?

Regulatory warnings state that Stoin may cause side effects that decrease alertness, affect vision, and lead to dizziness or impaired judgment. If these effects are experienced, regulatory warnings indicate that performing tasks requiring concentration, such as driving or operating heavy machinery, should be avoided.

Q: What happens if I miss a scheduled amount of Stoin?

Official administration guidance provides a specific protocol for managing missed doses to maintain consistent drug levels. This protocol outlines when to take a missed amount and when to skip it, strictly prohibiting the use of a double amount.

Q: Can Stoin be taken if I am currently taking an antidepressant?

Regulatory documentation notes that Stoin is an inhibitor of the CYP3A4 enzyme, which plays a role in metabolizing many other drugs. This potential metabolic interaction means that co-administration with drugs that are CYP3A4 substrates, which may include certain antidepressants, could lead to increased systemic exposure of that other drug.

Q: Does Stoin come in different strengths?

Official administration documents indicate that dosage requirements are strictly individualized and guided by a healthcare provider. The official protocol involves gradually increasing the dose over time (titration), which typically suggests that various strengths or forms are required to establish effective use.

Q: Why do doctors choose Stoin over other options?

The medicine is distinguished by its dual mechanism of action, as defined in its official documentation. Stoin combines a localized anesthetic component (Oxetacaine) with an antacid component. This formulation may be considered beneficial for providing rapid, targeted symptomatic relief at the site of upper gastrointestinal discomfort.

Q: Does Stoin have any known drug class warnings or alerts?

The drug is subject to additional monitoring by regulatory bodies to track new safety information. Official documents highlight specific critical risks classified as serious adverse reactions, including liver disease/failure, bone marrow suppression, and serious rash, which require immediate attention.

Q: What does 'contraindication' mean in relation to Stoin?

According to official eligibility guidelines, a contraindication is a clear statement that using Stoin is explicitly prohibited for patients with certain specific conditions. For Stoin, these conditions include severe kidney failure, a history of liver disease, or known hypersensitivity to any component, as use in these cases carries a risk of harm.

Q: Can Stoin change the effectiveness of common herbal remedies?

The product monographs specify the importance of ensuring a healthcare provider is aware of all concurrently used herbal tonics or supplements. This guidance addresses potential unknown or undocumented interactions between the medicine and other substances.

Q: Does Stoin interact with caffeine?

Product monographs state that certain items, including caffeine, chocolates, spicy foods, and fatty foods, are noted as substances to be avoided when using this medicine.

Q: What's the process for getting Stoin approved by a regulatory body like the FDA?

The regulatory process for drug approval involves several steps, starting with initial laboratory and animal testing. This is followed by human clinical trials designed to assess the drug's safety and effectiveness. Finally, a thorough review of all scientific data and manufacturing quality is conducted by the relevant regulatory authority before approval.

How should Stoin be stored and disposed of?

Official Storage and Disposal Requirements

Stoin (Oxetacaine oral suspension/gel) must be stored strictly according to official regulatory labeling to maintain its stability and effectiveness.

Storage Scope Requirement from Official Labeling
Temperature Store below 25 C or not exceeding 30 C.
Prohibitions Do not refrigerate or freeze the suspension.
Protection Protect from direct sunlight and excessive moisture.
Container Keep the bottle tightly closed in its original container.
In-Use Stability Use within 4 weeks after the bottle is first opened.

All medicine must be stored out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired product must not be thrown into household garbage or poured down the sink. Instead, it must be returned to a pharmacy or disposed of through an official drug take-back program according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stoin found in:

A-Z Index: